Excellent Cohort A Data From Final Primary Evaluation Period in Cynata GvHD Phase 1 Clinical Trial

Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP) is pleased to announce that the Primary Evaluation Period has been completed for the first cohort of patients in the clinical trial of its lead Cymerus™ mesenchymal stem cell product CYP-001, for the treatment of steroid-resistant graft versus host disease (GvHD).

As quoted in the press release:

• Efficacy data following completion of the Primary Evaluation Period (100 days) represents an improvement above the initial results announced in January
• Overall survival at Day 100 was 87.5%
• Overall Response rate by Day 100 was 100% (all eight participants showed an improvement in the severity of GvHD by at least one grade compared to baseline)
• Complete Response rate by Day 100 was 50% (GvHD signs/symptoms completely resolved in four out of eight patients)
• No treatment-related serious adverse events or safety concerns were identified during the Primary Evaluation Period

Click here to read the full press release.